Thromboxane A2 Regulates CXCL1 and CXCL8 Chemokine Expression in the Nasal Mucosa-Derived Fibroblasts of Chronic Rhinosinusitis Patients

PLoS One. 2016 Jun 28;11(6):e0158438. doi: 10.1371/journal.pone.0158438. eCollection 2016.

Abstract

Background: Chronic rhinosinusitis without nasal polyps (CRSsNP) is a common chronic disease and the etiology remains unclear. Thromboxane A2 (TXA2) participates in platelet aggregation and tissue inflammation. In this study, the CXCL1/8 chemokine and TXA2-TP receptor expression in the CRSsNP mucosa was investigated.

Experimental approach: Immunohistochemistry, chemokine release assay by ELISA, RT-PCR, Real-time PCR, Western blotting, pharmacological and siRNA knockdown analysis were applied in the CRSsNP tissue specimen and cultured nasal mucosa-derived fibroblasts.

Results: The immunohistochemistry results indicated that CXCL1 and CXCL8 were highly expressed in the CRSsNP mucosa compared with the controls; however, the TP receptors were expressed in both mucosa. Therefore, U46619 and IBOP, a TXA2 analog and TP agonist, were used to explore the role of TP activation in CXCL1/8 expression; both of these induced CXCL1/8 mRNA and protein expression in CRSsNP mucosa-derived fibroblasts. U46619 phosphorylated PI-3K, cyclic AMP (cAMP)/PKA, PKC, and cAMP response element (CREB). Activation of cAMP/PKA, PKC, and CREB was the major pathway for cxcl1/8 gene transcription. Pharmacological and siRNA knockdown analyses revealed that activation of cAMP/PKA and PKCμ/PKD pathways were required for CREB phosphorylation and PKA/C crosstalked with the PI-3K pathway.

Conclusion and implications: Our study provides the first evidence for abundant TP receptor and CXCL1/8 expression in human CRSsNP mucosa and for TXA2 stimulation inducing CXCL1/8 expression in nasal fibroblasts primarily through TP receptor, cAMP/PKA, PKCμ/PKD, and CREB-related pathways.

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / pharmacology
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Case-Control Studies
  • Cells, Cultured
  • Chemokine CXCL1 / genetics
  • Chemokine CXCL1 / metabolism*
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Fatty Acids, Unsaturated / pharmacology
  • Fibroblasts / drug effects
  • Fibroblasts / metabolism*
  • Interleukin-8 / genetics
  • Interleukin-8 / metabolism*
  • Nasal Mucosa / cytology
  • Nasal Mucosa / metabolism*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Protein Kinase C / metabolism
  • Receptors, Thromboxane A2, Prostaglandin H2 / agonists
  • Receptors, Thromboxane A2, Prostaglandin H2 / metabolism
  • Rhinitis / metabolism*
  • Rhinitis / pathology
  • Second Messenger Systems
  • Sinusitis / metabolism*
  • Sinusitis / pathology
  • Thromboxane A2 / metabolism*

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Chemokine CXCL1
  • Cyclic AMP Response Element-Binding Protein
  • Fatty Acids, Unsaturated
  • Interleukin-8
  • Receptors, Thromboxane A2, Prostaglandin H2
  • 7-(3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo(2.2.1)heptan-2-yl)-5-heptenoic acid
  • Thromboxane A2
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Phosphatidylinositol 3-Kinases
  • Protein Kinase C

Grants and funding

This work was supported by grants from National Science Council (NSC 102-2320-B-030-013-MY3) and Shin Kong Wu Ho-Su Memorial Hospital (SKH-8302-103-DR-25). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.